- Home
- RARE vs LTC Comparison
RARE vs LTC Comparison
Compare RARE & LTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | LTC |
|---|---|---|
| Founded | 2010 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2013 | 1994 |
Fundamental Metrics
Financial Performance| Metric | RARE | LTC |
|---|---|---|
| Price | $21.92 | $36.25 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 20 | 5 |
| Target Price | ★ $59.10 | $40.00 |
| AVG Volume (30 Days) | ★ 1.4M | 381.0K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 5.96% |
| EPS Growth | 7.31 | ★ 23.53 |
| EPS | N/A | ★ 0.48 |
| Revenue | ★ $673,000,000.00 | $262,854,000.00 |
| Revenue This Year | $13.12 | N/A |
| Revenue Next Year | $37.80 | N/A |
| P/E Ratio | ★ N/A | $72.63 |
| Revenue Growth | 20.13 | ★ 25.26 |
| 52 Week Low | $18.29 | $33.64 |
| 52 Week High | $40.17 | $40.80 |
Technical Indicators
Market Signals| Indicator | RARE | LTC |
|---|---|---|
| Relative Strength Index (RSI) | 39.50 | 39.56 |
| Support Level | $20.11 | $35.62 |
| Resistance Level | $23.44 | $37.00 |
| Average True Range (ATR) | 1.15 | 0.80 |
| MACD | -0.23 | -0.32 |
| Stochastic Oscillator | 11.98 | 38.24 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
About LTC LTC Properties Inc.
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.